Results 21 to 30 of about 23,497 (215)

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV. [PDF]

Arch Pharm (Weinheim)
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Leite DI, Macedo FB, Lima MMC, Brum IS, Oliveira JFM, Costa ACS, Duarte SC, Moon S, Moura SCB, Oliveira AP, Boechat N, Bastos MM.   +11 more
europepmc   +2 more sources

Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy [PDF]

, 2003
Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Abdurrahman, Z., Gough, K., Kovacs, C., Loutfy, M., Phillips, E., Raboud, J., Rachlis, A., Rubin, G., Thompson, C., Tseng, A., Walmsley, S.   +10 more
core   +2 more sources

Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

PLoS ONE, 2013
BackgroundNon-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants have been shown to emerge after interruption of suppressive NNRTI-based antiretroviral therapy (ART) using routine testing.
Anna Maria Geretti, Zoe Fox, Jeffrey A Johnson, Clare Booth, Jonathan Lipscomb, Lieven J Stuyver, Gilda Tachedjian, John Baxter, Giota Touloumi, Clara Lehmann, Andrew Owen, Andrew Phillips, INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group   +12 more
doaj   +1 more source

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

Frontiers in Virology, 2022
The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose   +4 more
doaj   +1 more source

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity. [PDF]

PLoS ONE, 2014
BACKGROUND: A sensitive, phenotypic reverse transcriptase (RT)-based drug susceptibility assay for the detection of etravirine (ETR) resistance in patient isolates was developed and compared with the results from direct sequencing and ultra-deep ...
Eva Agneskog, Piotr Nowak, Catharina Maijgren Steffensson, Maria Casadellà, Marc Noguera-Julian, Roger Paredes, Clas F R Källander, Anders Sönnerborg   +7 more
doaj   +1 more source

Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]

, 2018
Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T, Beloukas, Apostolos, Chadwick, David, Geretti, Anna Maria, Phillips, Richard O, Ruggiero, Alessandra, Sarfo, Fred S, Smith, Colette, Stockdale, Alexander J, Villa, Giovanni   +9 more
core   +3 more sources

Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. [PDF]

PLoS ONE, 2013
BACKGROUND:Non-adherence is one of the strongest predictors of therapeutic failure in HIV-positive patients. Virologic failure with subsequent emergence of resistance reduces future treatment options and long-term clinical success.
Viktor von Wyl, Thomas Klimkait, Sabine Yerly, Dunja Nicca, Hansjakob Furrer, Matthias Cavassini, Alexandra Calmy, Enos Bernasconi, Jürg Böni, Vincent Aubert, Huldrych F Günthard, Heiner C Bucher, Tracy R Glass, Swiss HIV Cohort Study   +13 more
doaj   +1 more source

Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014 [PDF]

, 2016
Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited.
Aghasadeghi, M.R., Baesi, K., Davarpanah, M.A., McFarland, W., Moradi, A., Naziri, H., Tabarraei, A.   +6 more
core   +1 more source

Prevalence and Outcomes of Recycling NNRTIs Despite Documented NNRTI Resistance in HIV-Infected Children and Youth [PDF]

AIDS Patient Care and STDs, 2014
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in pediatric patients; however, rapid development of resistance, due to non-adherence and cross-resistance, results in their discontinuation and limits their recycling. We evaluated the clinical experience of recycling NNRTIs despite documented NNRTI resistance (NNRTI-R), and ...
Allison L, Agwu, Jennifer Y, Chang, Ryan E, Wiegand, John T, Wheeling, Beverly A, Bohannon, Kenneth L, Dominguez   +5 more
openaire   +2 more sources

Evaluation of subcutaneous proleukin (Interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants [PDF]

, 2006
Background: ESPRIT, is a phase III, open-label, randomized, international clinical trial evaluating the effects of subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART) versus ART alone on HIV-disease progression and death in ...
Arduino, R., Austin, D., ESPRIT Research Group, Knysz, B., Law, M. G., Lopez, J. C., Pereira, L. C., Pett, S. L., Pollack, S., Reiss, P., Tambussi, G., Wand, H., Writing Group   +12 more
core   +13 more sources